Get the Stockscreener App
112.69
1.93%
2.13
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $112.69, with a volume of 8.09M.
It is up +1.93% in the last 24 hours and down -0.27% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$110.56
Open:
$110.74
24h Volume:
8.09M
Relative Volume:
1.28
Market Cap:
$139.83B
Revenue:
$28.80B
Net Income/Loss:
$6.31B
P/E Ratio:
22.42
EPS:
5.0273
Net Cash Flow:
$9.37B
1W Performance:
+0.53%
1M Performance:
-0.27%
6M Performance:
+0.27%
1Y Performance:
+33.88%
1-Day Range:
$109.66
$113.59
1-Week Range:
$108.46
$114.86
52-Week Range:
$83.98
$121.83
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
112.69 | 137.18B | 28.80B | 6.31B | 9.37B | 5.0273 |
|
LLY
Lilly Eli Co
|
839.87 | 734.96B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
188.64 | 447.90B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
233.91 | 417.90B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.39 | 253.54B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
89.19 | 223.58B | 63.43B | 16.42B | 14.72B | 6.4861 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences (GILD) Laps the Stock Market: Here's Why - sharewise.com
RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD) - Insider Monkey
Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways - Yahoo Finance
How Gilead Sciences Inc. (Common Stock) (GIS0) stock responds to bond marketMarket Sentiment Summary & High Conviction Buy Zone Picks - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock recover faster than industry2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo
Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock. - Barron's
Gilead stock faces potential hit if Biktarvy is Trump’s price cut target - Investing.com
Potential Price Pressures for Gilead (GILD) Shares - GuruFocus
RBC on Gilead Sciences (GILD): 'Could Biktarvy Be The $137 Pill Trump Wants To Cut To $18' - StreetInsider
Marginal Zone Lymphoma Market Growth Projections 2024-2034: DelveInsight Analysis | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma - The Globe and Mail
Immatics Appoints Venkat Ramanan as Chief Financial Officer - GlobeNewswire Inc.
Using flow based indicators on Gilead Sciences Inc.2025 Sector Review & Short-Term High Return Strategies - newser.com
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - MSN
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
How to integrate Gilead Sciences Inc. into portfolio analysis toolsEarnings Miss & Weekly High Conviction Trade Ideas - newser.com
What Do Analysts Think About Gilead Sciences (GILD)? - Insider Monkey
Gilead signs $34.5M deal for Hanmi/HHP’s I.V.-to-oral drug tech - BioWorld MedTech
Gilead Sciences Begins On New California Manufacturing Hub - Construction Equipment Guide
One Wealth Advisors LLC Has $1.02 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Earnings visualization tools for Gilead Sciences Inc.2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Capital Investment Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Raleigh Capital Management Inc. Sells 6,315 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GC Wealth Management RIA LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Avior Wealth Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Hong Kong's Health Hope Pharma enters into virology deal with Gilead Sciences - BioSpectrum Asia
Will Gilead Sciences Inc. stock keep outperforming rivals2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
Gilead pumps up virology pipeline with drug transporter deal - Fierce Biotech
What analyst consensus implies for Gilead Sciences Inc. (GIS) stockSell Signal & Smart Allocation Stock Tips - newser.com
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences - PR Newswire UK
Hanmi, HHP license oral drug delivery compound to Gilead By Investing.com - Investing.com Canada
Hanmi Pharmaceutical Signs Global Licensing Agreement with Gilead Sciences and Health Hope Pharma for Encequidar - Korea IT Times
Hanmi's Oral Delivery Platform Compound Licensed to Gilead - Eastern Progress
Real time scanner hits for Gilead Sciences Inc. explainedQuarterly Portfolio Summary & Reliable Intraday Trade Plans - newser.com
Hanmi's oral delivery platform compound licensed to Gilead - MarketScreener
Hanmi Pharm licenses oral drug delivery compound to Gilead Sciences - StreetInsider
Short interest data insights for Gilead Sciences Inc.2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Gilead Sciences, Inc. $GILD Shares Sold by First County Bank CT - MarketBeat
Hanmi sells Encequidar oral absorption tech to Gilead in up to $34.5M dealCHOSUNBIZ - Chosun Biz
Will Gilead Sciences Inc. stock deliver strong dividend growth2025 Top Decliners & Weekly Return Optimization Plans - newser.com
Morgan Stanley Maintains Buy on Gilead Sciences (GILD) - Insider Monkey
Why Gilead Sciences Inc. (GIS) stock is a must watch tickerMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Gilead Sciences, Inc. (NASDAQ:GILD) Is Favoured by Institutional Owners Who Hold 88% of the Company - 富途牛牛
Old Port Advisors Buys Shares of 7,321 Gilead Sciences, Inc. $GILD - MarketBeat
What analysts say about Gilead Sciences Inc GIS stockREITs Market Trends & Free Risk Assessment and Control - Early Times
Kathmere Capital Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
State of Alaska Department of Revenue Sells 6,285 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum - Yahoo Finance
How Gilead Sciences Inc. (Common Stock) (GIS0) stock moves in volatile trading sessions2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com
Is Gilead Sciences Inc. (GIS) stock included in top ETFsBuy Signal & Stock Portfolio Risk Management - newser.com
JPMorgan Lifts Gilead Sciences, Inc. (GILD)’s Price Target To $145, Maintains Overweight Rating - MSN
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):